Liquidia Co. (NASDAQ:LQDA) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in Liquidia Co. (NASDAQ:LQDA) by 855.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 235,393 shares of the company’s stock after purchasing an additional 210,753 shares during the period. JPMorgan Chase & Co. owned about 0.28% of Liquidia worth $2,354,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in LQDA. Profund Advisors LLC raised its position in Liquidia by 31.6% during the second quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock worth $173,000 after acquiring an additional 3,466 shares during the period. Marshall Wace LLP acquired a new position in Liquidia during the second quarter worth $545,000. Squarepoint Ops LLC raised its position in Liquidia by 53.4% during the second quarter. Squarepoint Ops LLC now owns 82,272 shares of the company’s stock worth $987,000 after acquiring an additional 28,638 shares during the period. The Manufacturers Life Insurance Company raised its position in Liquidia by 25.2% during the second quarter. The Manufacturers Life Insurance Company now owns 22,706 shares of the company’s stock worth $272,000 after acquiring an additional 4,572 shares during the period. Finally, Bluefin Capital Management LLC acquired a new position in Liquidia during the second quarter worth $277,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 6,249 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the completion of the sale, the insider now directly owns 270,388 shares in the company, valued at $3,185,170.64. This trade represents a 2.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Russell Schundler sold 16,393 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the sale, the general counsel now owns 573,478 shares of the company’s stock, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,055 shares of company stock valued at $836,299. 30.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

LQDA has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of Liquidia in a research report on Thursday, January 9th. Wells Fargo & Company began coverage on shares of Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 target price for the company. Lifesci Capital began coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. Finally, Scotiabank began coverage on shares of Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.38.

Liquidia Trading Up 5.7 %

Shares of LQDA opened at $13.62 on Wednesday. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.99. The firm has a 50-day moving average price of $11.34 and a 200 day moving average price of $11.03. The firm has a market capitalization of $1.15 billion, a P/E ratio of -8.36 and a beta of 0.23.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).